Mesalamine (generic), Asacol, Pentasa

Mesalamine (generic), Asacol, Pentasa Newswire

Comprehensive Real-Time News Feed for Mesalamine (generic), Asacol, Pentasa.

Results 1 - 20 of 36 in Mesalamine (generic), Asacol, Pentasa

  1. Actavis Pays $40 Million Upfront; Snags Option To BuyRead the original story

    21 hrs ago | BioSpace

    Rhythm expects to initiate a Phase 2b clinical trial for the treatment of diabetic gastroparesis by early 2015. upfront payment to Rhythm, and will have the option to acquire Rhythm Health, Inc. and the worldwide rights to relamorelin for an undisclosed amount following the completion of the Phase 2b study.

    Comment?

  2. Georgia gets $1.78M in Shire Pharmaceuticals settlementRead the original story w/Photo

    Tuesday Oct 7 | Business Journal

    Shire Pharmaceuticals LLC will pay $56.5 million, including $1.78 million to Georgia Medicaid, to resolve allegations it violated the False Claims Act as a result of its marketing and promotion of several drugs. Shire Pharmaceuticals LLC will pay $56.5 million, including $1.78 million to Georgia Medicaid, to resolve allegations it violated the False Claims Act as a result of its marketing and promotion of several drugs.

    Comment?

  3. Corporate Whistleblower Center Urges Drug Company Insiders to Call...Read the original story w/Photo

    Tuesday Oct 7 | PRWeb

    The Corporate Whistleblower Center is urging pharmaceutical company representatives, managers, or physicians to call them at 866-714-6466, if they have well documented proof a drug company is selling a drug product under false pretenses, or if the company is selling the drug off label. There was a recent announcement about a multi million dollar reward to a whistleblower who stepped forward with this exact type of information.

    Comment?

  4. Medicaid Program Gets Boost From Pharmaceutical SettlementRead the original story w/Photo

    Sep 18, 2014 | Ctnewsjunkie.com

    The release of a new iPhone has almost become an Autumn holiday - especially for the hundreds of eager customers who more>> Data is vitally important to most nonprofits. It is a key component for seeking grant funds, gives a clear picture of... more>> Connecticut's Medicaid program received $388,145 this month as part of a broader $56.5 million settlement that states and the federal government reached with Shire Pharmaceuticals.

    Comment?

  5. Multistate coalition, U.S. reach $56.5 million agreement with pharmaceutical makerRead the original story w/Photo

    Tuesday Sep 30 | KGNS-TV Laredo

    Texas Attorney General Greg Abbott, 48 other state attorneys general and the federal government secured a $56.5 million agreement with Pennsylvania-based drug maker Shire Pharmaceuticals, LLC. The agreement resolves the states' Medicaid fraud investigation against Shire for unlawfully promoting five of its drugs: Adderrall XR, Vyvanse, Daytrona, Lialda and Pentasa. Under the settlement agreement, Shire must pay the State of Texas a total of $4.78 million.

    Comment?

  6. Ohio gets $2 million Share in Shire Pharmaceuticals settlementRead the original story w/Photo

    Sunday Sep 28 | Norwalk Reflector

    Ohio Attorney General Mike DeWine announced that Ohio's share in a settlement to resolve allegations against a Pennsylvania based pharmaceutical company exceeds $2 million. Ohio joined with several other states and the federal government to settle allegations that Shire Pharmaceuticals LLC engaged in off-label marketing campaigns that improperly promoted the drugs Adderrall XR, Vyvanse, Daytrona, Lialda, and Pentasa.

    Comment?

  7. AbbVie considering $7B more in financing for Shire deal, Bloomberg reportsRead the original story

    Sep 12, 2014 | Theflyonthewall.com

    Shire to pay $56.5M to resolve False Claims Act allegations Pharmaceutical company Shire Pharmaceuticals will pay $56.5M to resolve civil allegations that it violated the False Claims Act as a result of its marketing and promotion of several drugs, the Justice Department announced. Shire, located in Wayne, Pennsylvania, manufactures and sells pharmaceuticals, including Adderall XR, Vyvanse and Daytrana, which are approved for the treatment of attention deficit hyperactivity disorder, and Pentasa and Lialda, which are approved for the treatment of mild to moderate active ulcerative colitis.

    Comment?

  8. MoreRead the original story w/Photo

    Thursday Sep 25 | WBOC-TV Salisbury

    Delaware Attorney General Beau Biden announced Thursday that Shire Pharmaceuticals will pay Delaware $137,000 as part of a national settlement with state and federal governments to resolve allegations that the company improperly marketed its drugs for off-label uses. The entire settlement totals $56.5 million for Delaware, the federal government and many other states.

    Comment?

  9. Florida Obtains More Than $900,000 from Shire Pharmaceuticals, LLCRead the original story w/Photo

    Thursday Sep 25 | Capital Soup

    Attorney General Pam Bondi, 49 other attorneys general, and the federal government today reached a $56.5 million settlement with Shire Pharmaceuticals, LLC, a Pennsylvania based company, to resolve allegations that the company engaged in off-label marketing campaigns that improperly promoted five of its drugs: Adderrall XR, Vyvanse, Daytrona, Lialda and Pentasa. Adderrall XR, Vyvanse and Daytrona are United States Food and Drug Administration approved for treatment of Attention Deficit Hyperactivity Disorder, and Lialda and Pentasa are approved for treatment of mildly to moderately active ulcerative colitis.

    Comment?

  10. Shire Pharmaceuticals Pays $56.5 Million to Resolve Off-Label Marketing AllegationsRead the original story

    Thursday Sep 25 | South Dakota Attorney General

    Attorney General Marty Jackley announced today that South Dakota has joined with other states and the federal government to settle allegations that Shire Pharmaceuticals, LLC engaged in off-label marketing campaigns that improperly promoted five of its drugs: Adderrall XR, Vyvanse, Daytrona, Lialda and Pentasa. Shire Pharmaceuticals will pay the states and the federal government $56.5 million, of which $48.1 million will go to the Medicaid programs to resolve civil allegations that the company unlawfully marketed these drugs and thereby caused false claims to be submitted to the government health care programs.

    Comment?

  11. Schuette Secures $1.6 Million for Michigan in Historic Settlement...Read the original story

    Thursday Sep 25 | State of Michigan

    Michigan Attorney General Bill Schuette today announced that Michigan will receive more than $1.6 million from a global settlement to resolve civil allegations that Pennsylvania drug manufacturer Shire Pharmaceuticals LLC, a unit of Ireland-based Shire Pharmaceuticals PLC, unlawfully marketed three Attention Deficit Hyperactivity Disorder drugs and two drugs intended to treat mild to moderate ulcerative colitis. The settlement resolves allegations Shire engaged in off-label marketing to improperly promote five of its drugs to medical providers including: Adderrall XR, Vyvanse, Daytrana, Lialda, and Pentasa.

    Comment?

  12. Shire to pay $59M to settle lawsuits over false drug claimsRead the original story w/Photo

    Thursday Sep 25 | Business Journal

    Drug company Shire has agreed to pay $59.4 million to various states for making a host of unsupported claims regarding five of its drugs for attention deficit hyperactivity disorder and ulcerative colitis. Under the settlement, announced Wednesday, the company admits no wrongdoing despite charges that it claimed its ADHD drug Adderall XR can help "poor academic performance, loss of employment, criminal behavior, traffic accidents and sexually transmitted disease," according to the federal Department of Justice.

    Comment?

  13. Shire Pharmaceuticals LLC to Pay $56.5 Million to Resolve False...Read the original story

    Thursday Sep 25 | Customer Interaction Solutions

    PHILADELPHIA, Sept. 24 -- The U.S. Attorney for the Eastern District of Pennsylvania issued the following news release: Pharmaceutical company Shire Pharmaceuticals LLC will pay $56.5 million to resolve allegations that it violated the False Claims Act as a result of its marketing and promotion of several drugs, the Justice Department announced today.

    Comment?

  14. Shire's $56.5 mln deal is only a fraction of salesRead the original story w/Photo

    Wednesday Sep 24 | MarketWatch

    The Department of Justice had charged Shire with making unsupported claims for its Adderall XR treatment for attention deficit hyperactivity disorder, including that it would prevent "poor academic performance, loss of employment, criminal behavior, traffic accidents and sexually transmitted disease." Justice officials say Shire made the claims between January 2004 and December 2007, and promoted the drug for treatment of conduct disorder without getting approval from the U.S. Food and Drug Administration.

    Comment?

  15. Shire pays $56.5M to resolve whistleblower claims it improperly marketed drugsRead the original story w/Photo

    Wednesday Sep 24 | Business Journal

    Shire Pharmaceuticals paid the government $56.5 million to settle claims brought by whistleblowers that it improperly marketed several drugs. Shire Pharmaceuticals LLC will pay $56.5 million to resolve allegations that it violated the False Claims Act as a result of its marketing and promotion of several drugs, federal prosecutors in Philadelphia said Wednesday.

    Comment?

  16. Shire to pay $56.5M over ADHD drugRead the original story w/Photo

    Wednesday Sep 24 | Philly.com

    Shire Pharmaceuticals L.L.C. will pay $56.5 million to settle allegations that it inappropriately promoted the sale of ADHD medicine, among other drugs, the U.S. Attorney's Office in Philadelphia said Wednesday. Shire is registered in the Channel Islands and headquartered in Dublin, but operates from the United States, including Wayne.

    Comment?

  17. Shire to pay $56.5M to resolve False Claims Act allegationsRead the original story

    Sep 10, 2014 | Theflyonthewall.com

    Shire to pay $56.5M to resolve False Claims Act allegations Pharmaceutical company Shire Pharmaceuticals will pay $56.5M to resolve civil allegations that it violated the False Claims Act as a result of its marketing and promotion of several drugs, the Justice Department announced. Shire, located in Wayne, Pennsylvania, manufactures and sells pharmaceuticals, including Adderall XR, Vyvanse and Daytrana, which are approved for the treatment of attention deficit hyperactivity disorder, and Pentasa and Lialda, which are approved for the treatment of mild to moderate active ulcerative colitis.

    Comment?

  18. Case StudiesRead the original story

    Sep 16, 2014 | Pharmacy Times

    CASE 1 CC is a 39-year-old man who presents to the pharmacy after being bitten by a tick. CC expresses concern about potentially acquiring a tick-borne illness.

    Comment?

  19. Rx Product NewsRead the original story

    Aug 15, 2014 | Pharmacy Times

    Delzicol Marketed by: Actavis Pharma, Inc Indication: The FDA has approved Delzicol delayed-release capsules to treat mildly to moderately active ulcerative colitis in patients 12 years and older.

    Comment?

  20. mesalamine, Pentasa, Rowasa, Asacol, Asacol HD, Lialda, Canasa, Apriso, DelzicolRead the original story w/Photo

    Aug 1, 2014 | MedicineNet

    Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.

    Comment?